Health News

Nektar Announces Preliminary Topline Results from Phase 2 Efficacy Study for NKTR-181 in Chronic Pain Patients with Osteoarthritis of the Knee

Author: Australian Business

SAN FRANCISCO, Sept. 26, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced the preliminary topline results from a Phase 2 study of NKTR-181 for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis of the knee. The Phase 2 study utilized a......

More...

More Articles...

Beckman Coulter Receives FDA Clearance of AccuTnI+3 Troponin I Assay on UniCel DxI Immunoassay Systems
It Takes Guts! 21 Day Challenge Not Your Typical 5K
Affordable Care Act Upgrades Will Require Pennsylvania Health and Human Services System Outage
Analysis of the Global Type 2 Diabetes Therapeutics Market
Patricia A. English is recognized by Continental Who's Who as a Pinnacle Professional
Mary Lee Zawadski, CAP, CAC, CADC is recognized by Continental Who's Who as a Pinnacle Professional
Nuclear Medicine Market Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] Stable Isotopes (Deuterium, C-13) - Global Trends Forecast to 201
MRM Eyes Elite Athletes with Launch of Whey-Alternative Protein During 2013 Olympia Weekend
2013 National Safety Council Congress Expo looks toward the future of safety
As New Research Bolsters Long-Term Anti-Diabetes Benefits of Weight Loss Surgery, Dr. Feiz Associates Reminds the Public of the Illness's Dangers

Page 1408 of 1908